KOD vs. INDV, NAMS, CNTA, AMRX, QURE, XENE, VKTX, CGON, MOR, and GMTX
Should you be buying Kodiak Sciences stock or one of its competitors? The main competitors of Kodiak Sciences include Indivior (INDV), NewAmsterdam Pharma (NAMS), Centessa Pharmaceuticals (CNTA), AMNEAL PHARMACEUTICALS (AMRX), uniQure (QURE), Xenon Pharmaceuticals (XENE), Viking Therapeutics (VKTX), CG Oncology (CGON), MorphoSys (MOR), and Gemini Therapeutics (GMTX). These companies are all part of the "pharmaceutical products" industry.
Kodiak Sciences vs. Its Competitors
Indivior (NASDAQ:INDV) and Kodiak Sciences (NASDAQ:KOD) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and earnings.
In the previous week, Kodiak Sciences had 2 more articles in the media than Indivior. MarketBeat recorded 5 mentions for Kodiak Sciences and 3 mentions for Indivior. Kodiak Sciences' average media sentiment score of 0.38 beat Indivior's score of 0.32 indicating that Kodiak Sciences is being referred to more favorably in the news media.
Indivior has a net margin of 6.65% compared to Kodiak Sciences' net margin of 0.00%. Indivior's return on equity of -86.28% beat Kodiak Sciences' return on equity.
60.3% of Indivior shares are held by institutional investors. Comparatively, 89.1% of Kodiak Sciences shares are held by institutional investors. 45.9% of Kodiak Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Indivior has higher revenue and earnings than Kodiak Sciences. Kodiak Sciences is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.
Indivior has a beta of 0.7, meaning that its stock price is 30% less volatile than the S&P 500. Comparatively, Kodiak Sciences has a beta of 2.67, meaning that its stock price is 167% more volatile than the S&P 500.
Indivior presently has a consensus price target of $22.00, suggesting a potential downside of 5.05%. Kodiak Sciences has a consensus price target of $13.00, suggesting a potential downside of 13.68%. Given Indivior's stronger consensus rating and higher probable upside, equities research analysts clearly believe Indivior is more favorable than Kodiak Sciences.
Summary
Indivior beats Kodiak Sciences on 11 of the 16 factors compared between the two stocks.
Get Kodiak Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for KOD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding KOD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Kodiak Sciences Competitors List
Related Companies and Tools
This page (NASDAQ:KOD) was last updated on 10/5/2025 by MarketBeat.com Staff
Free KOD Stock Alerts